Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva granted tentative approval for generic osteoporosis drug
Teva is currently involved in patent litigation concerning this product in the US District Court of Indiana. A trial date has not been set.
Teva is currently involved in patent litigation concerning this product in the US District Court of Indiana. A trial date has not been set.
The company sold 4.03 million shares of its common stock at $1.32 per share, and warrants to purchase up to 2.01 million shares of its common stock for
The 12 week randomized double-blind, placebo-controlled study will evaluate safety, efficacy and tolerability of BCI-540 to determine whether 80mg given once or three times daily is effective in
Under the terms of the agreement, Garden State Nutritionals (GSN) will manufacture and deliver a powerful and proprietary anti-aging, antioxidant nutritional supplement for the company. The company will
Results from in vivo human tumor models in mice demonstrated significant inhibition of tumor growth in a broad range of cancer types. In c-Met driven gastric cancer and
Funding from the financing will allow for the initiation of Phase III studies of Paratek’s broad-spectrum antibiotic, PTK 0796, which is being developed to treat serious, often life-threatening
The Phase II trial is an open-label, multi-center, monotherapy study of KOS-1584 in patients with measurable advanced or metastatic non-small cell lung cancer who have previously received only
This office is expected to grow rapidly under the leadership of Dr Kornilov and will be primarily focused on supporting the company’s Global Clinical Development brand. Armand Czaplinski,
The fees and milestone payments due to HGS under the original Syncria agreement, some of which have already been received, could amount to as much as $183 million
A total of 40 patients with a variety of hematological malignancies, including leukemias and lymphomas, have been enrolled in the study, with 40 patients evaluable for safety and